Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Abroad (travel likely)RecruitingPHASE1, PHASE2
Conditions
Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma · Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer · Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer · Advanced Solid Tumors · Advanced or Metastatic KRAS-mutant Tumor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
NEXT Oncology Dallas, Dallas, Texas, United States
Contact: Principal Investigator (Shiraj Sen, MD, PhD)Next Oncology, San Antonio, San Antonio, Texas, United States
Contact: Principal Investigator (Anthony Tolcher, MD, FRCPC, FACP, FASCO)Princess Margareth Cancer Center, Toronto, Ontario, Canada
Contact: Principal Investigator (Anna Spreafico, MD, PhD)Oxford University Hospital, Headington, Oxford, United Kingdom
Contact: Principal Investigator (Mark Middleton, MD, FRCP (UK), PhD)Magdalena Kielak, MD (Sub-investigator)Simon Lord, MD (Sub-investigator)